Managing the osteoporotic patient today

Reginster, Jean-Yves

doi:10.1016/j.bone.2007.02.004

Request a copy

Article (Scientific journals)

Managing the osteoporotic patient today

Reginster, Jean-Yves

2007 • In BONE, 40 (5, Suppl. 1), p. 12-S18

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/20289

DOI
10.1016/j.bone.2007.02.004

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Managing the osteoporotic patient today.pdf

Publisher postprint (180.95 kB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

adherence; antifracture efficacy; back pain; height loss; postmenopausal osteoporosis; quality of life; strontium ranelate

Abstract :

[en] as reduced pain and disability. The unique mechanism of action of strontium ranelate corrects bone turnover so that it is rebalanced in favor of bone formation. Double-blind, placebo-controlled studies in postmenopausal osteoporosis show it to be effective in reducing vertebral and hip fracture risks. Treatment efficacy has been documented across a wide range of patient profiles and appears to be independent of all the major determinants of fracture risk, including the severity of the disease at baseline, the number of prevalent fractures, and the age of the patient. This antifracture efficacy translates into clinical benefits, including a reduction in the rate of height loss and an increase in the number of patients free of back pain. Strontium ranelate is also one of the few anti osteoporotic drugs with data to demonstrate an improvement in quality of life indices. The rates of compliance with treatment were over 80% in phase 3 studies, reflecting the tolerability and safety profile and the ease of administration of this agent. Strontium ranelate thus offers significant clinical benefits in terms of efficacy, tolerability, and ease of administration in the treatment of postmenopausal women with osteoporosis fractures. (c) 2007 Elsevier Inc. All rights reserved.

Disciplines :

Endocrinology, metabolism & nutrition

Author, co-author :

Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique

Language :

English

Title :

Managing the osteoporotic patient today

Publication date :

May 2007

Journal title :

BONE

ISSN :

8756-3282

eISSN :

1873-2763

Publisher :

Elsevier Science Inc, New York, United States - New York

Volume :

Issue :

5, Suppl. 1

Pages :

S12-S18

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 28 August 2009

Statistics

Number of views

42 (5 by ULiège)

Number of downloads

2 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Who are candidates for prevention and treatment for osteoporosis? Osteoporos Int 7 (1997) 1-6.
Gullberg B., Johnell O., and Kanis J.A. Worldwide projections for hip fracture. Osteoporos. Int. 7 (1997) 407-413
National Osteoporosis Society UK (www.nos.org.uk) and National Osteoporosis Foundation USA (www.nof.org). Accessed: November 2006.
Randell A., Sambrook P.N., Nguyen T.V., Lapsley H., Jones G., Kelly P.J., et al. Direct clinical and welfare costs of osteoporotic fractures in elderly men and women. Osteoporos. Int. 5 (1995) 427-432
Donaldson L.J., Cook A., and Thomson R.G. Incidence of fractures in a geographically defined population. J. Epidemiol. Community Health 44 (1990) 241-245
Cooper C., Campion G., and Melton III L.J. Hip fractures in the elderly: a world-wide projection. Osteoporos. Int. 2 (1992) 285-289
Cummings S.R., and Melton L.J. Epidemiology and outcomes of osteoporotic fractures. Lancet 359 (2002) 1761-1767
Cooper C., Atkinson E.J., Jacobsen S.J., O'Fallon W.M., and Melton III L.J. Population-based study of survival after osteoporotic fractures. Am. J. Epidemiol. 137 (1993) 1001-1005
Keene G.S., Parker M.J., and Pryor G.A. Mortality and morbidity after hip fractures. BMJ 307 (1993) 1248-1250
Leibson C.L., Tosteson A.N., Gabriel S.E., Ransom J.E., and Melton L.J. Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J. Am. Geriatr. Soc. 50 (2002) 1644-1650
Magaziner J., Lydick E., Hawkes W., Fox K.M., Zimmerman S.I., Epstein R.S., et al. Excess mortality attributable to hip fracture in white women aged 70 years and older. Am. J. Public Health 87 (1997) 1630-1636
Magaziner J., Simonsick E.M., Kashner T.M., Hebel J.R., and Kenzora J.E. Predictors of functional recovery one year following hospital discharge for hip fracture: a prospective study. J. Gerontol. 45 (1990) M101-M107
Melton III L.J., Chrischilles E.A., Cooper C., Lane A.W., and Riggs B.L. Perspective. How many women have osteoporosis?. J. Bone Miner. Res. 7 (1992) 1005-1010
Delmas P.D., van de Langerijt L., Watts N.B., Eastell R., Genant H., Grauer A., et al. IMPACT Study Group. Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study. J. Bone Miner. Res. 20 (2005) 557-563
Gold D.T. The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Bone 18 (1996) 185S-189S
Klotzbuecher C.M., Ross P.D., Landsman P.B., Abbott III T.A., and Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J. Bone Miner. Res. 15 (2000) 721-739
Hasserius R., Karlsson M.K., Nilsson B.E., Redlund-Johnell I., and Johnell O. European Vertebral Osteoporosis Study. Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study. Osteoporos. Int. 14 (2003) 61-68
Lindsay R., Silverman S.L., Cooper C., Hanley D.A., Barton I., Broy S.B., et al. Risk of new vertebral fracture in the year following a fracture. JAMA 285 (2001) 320-323
Black D.M., Arden N.K., Palermo L., Pearson J., and Cummings S.R. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J. Bone Miner. Res. 14 (1999) 821-828
Cauley J.A., Thompson D.E., Ensrud K.C., Scott J.C., and Black D.M. Risk of mortality following clinical fractures. Osteoporos. Int. 11 (2000) 556-561
Center J.R., Nguyen T.V., Schneider D., Sambrook P.N., and Eisman J.A. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353 (1999) 878-882
Sanders K.M., Nicholson G.C., Watts J.J., Pasco J.A., Henry M.J., Kotowicz M.A., et al. Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective?. Bone 38 (2006) 694-700
Seeman E., Vellas B., Benhamou C., Aquino J.P., Semler J., Kaufman J.M., et al. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J. Bone Miner. Res. 21 (2006) 1113-1120
Kanis J.A. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO Report. WHO Study Group. Osteoporos. Int. 4 (1994) 368-381
Martin J.C. Appendicular measurements in screening women for low axial bone mineral density. Br. J. Radiol. 69 (1996) 234-240
Guglielmi G., Grimston S.K., Fischer K.C., and Pacifici R. Osteoporosis: diagnosis with lateral and posteroanterior dual x-ray absorptiometry compared with quantitative CT. Radiology 192 (1994) 845-850
Jergas M., Grampp S., Lang P., Engelke K., Godfredsen N., Lu Y., et al. Measurements of bone density at the axial skeleton: a comparative analysis of quantitative computed tomography and dual x-ray absorptiometry. J. Bone Miner. Res. 9 (1994) S406
Faulkner K. Measurement of axial and peripheral bone mass by QCT. National Osteoporosis Foundation; bone mass measurement in osteoporosis and other diseases (1995 (November))
Lafferty F.W., and Rowland D.Y. The superiority of spinal supine lateral QDR and QCT over spinal AP-QDR in detecting vertebral compression fractures. J. Bone Miner. Res. 9 (1994) S274
Yu W., Gluer C.-C., Grampp S., Jergas M., Fuerst T., Wu C.Y., et al. Spinal bone mineral assessment in postmenopausal women: a comparison between dual x-ray absorptiometry and quantitative computed tomography. Osteoporos. Int. 5 (1995) 433-439
Kazakia GJ, Majumdar S. New imaging technologies in the diagnosis of osteoporosis. Rev Endocr Metab Disord (in press).
Marshall D., Johnell O., and Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312 (1996) 1254-1259
Davison K.S., Siminoski K., Adachi J.D., Hanley D.A., Goltzman D., Hodsman A.B., et al. Bone strength: the whole is greater than the sum of its parts. Semin. Arthritis Rheum. 36 (2006) 22-31
Shea B, Wells G, Cranney A, Zytaruk N, Robinson V, Griffith L, et al. Osteoporosis Methodology Group; Osteoporosis Research Advisory Group. Calcium supplementation on bone loss in postmenopausal women. Cochrane Database Syst Rev 2004;(1):CD004526. Review.
Meunier P.J., Roux C., Seeman E., Ortolani S., Badurski J.E., Spector T.D., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. 350 (2004) 459-468
Reginster J.Y., Seeman E., De Vernejoul M.C., Adami S., Compston J., Phenekos C., et al. Strontium ranelate reduces the risk of nonvertebral fractures in post-menopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) Study. J. Clin. Endocrinol. Metab. 90 (2005) 2816-2822
Population division of the development of economic and social affairs of the Nations Secretariat, world population prospects: The 2002 revision and world urban prospects (http://esa.un.org/unpp).
Reginster J.Y., Meunier P.J., Roux C., Compston J., and Ortolani S. Strontium ranelate: an anti-osteoporotic treatment demonstrated vertebral and nonvertebral anti-fracture efficacy over 5 years in post menopausal osteoporotic women. Osteoporos. Int. 17 Suppl. 2 (2006) S14 [OC 24]
Seeman E., Vellas B., Benhamou C.L., Aquino J.P., Semler J., Kaufman J.M., et al. Sustained 5-year vertebral and non-vertebral risk reduction with strontium ranelate in elderly women with osteoporosis. Osteoporos. Int. 17 Suppl. 2 (2006) S18 [OC 39]
Roux C., Reginster J.Y., Fechtenbaum J., Kolta S., Sawicki A., Tulassay Z., et al. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J. Bone Miner. Res. 21 (2006) 536-542
Siminoski K., Warshawski R.S., Jen H., and Lee K. The accuracy of historical height loss for the detection of vertebral fractures in postmenopausal women. Osteoporos Int. 17 (2006) 290-296
Ismail A.A., Cooper C., Felsenberg D., Varlow J., Kanis J.A., Silman A.J., et al. Number and type of vertebral deformities: epidemiological characteristics and relation to back pain and height loss. European Vertebral Osteoporosis Study Group. Osteoporos. Int. 9 (1999) 206-213
Nevitt M.C., Ettinger B., Black D.M., Stone K., Jamal S.A., Ensrud K., et al. The association of radiographically detected vertebral fracture with back pain and function: a prospective study. Ann. Intern. Med. 128 (1998) 793-800
Marquis P., De La Loge C., Diaz-Curiel M., Spector T., and Meunier P.J. Beneficial effects of strontium ranelate on the quality of life in patients with vertebral osteoporosis (SOTI study). Osteoporos. Int. 16 Suppl. 3 (2005) S54
Van Schoor N.M., Smit J.H., Twisk J.W., and Lips P. Impact of vertebral deformities, osteoarthritis, and other chronic diseases on quality of life: a population-based study. Osteoporos. Int. 16 (2005) 749-756
Lydick E., Martin A., and Yawn B. Impact of fears on quality of life in patients with a silent disease: osteoporosis. Clin. Ther. 18 (1996) 1307-1315
Galsworthy T.D., and Wilson P.L. Osteoporosis: it steals more than bone. Am. J. Nurs. 96 (1996) 26-33
Cook D.J., Guyatt G.H., Adachi J.D., Clifton J., Griffith L.E., Epstein R.S., et al. Quality of life issues in women with vertebral fractures due to osteoporosis. Arthritis Rheum. 36 (1993) 750-756
de la Loge C., Sullivan K., Pinkney R., Marquis P., Roux C., and Meunier P.J. Cross-cultural validation and analysis of responsiveness of the QUALIOST®: QUAlity of Life questionnaire In OSTeoporosis. Health Qual Life Outcomes 3 (2005) 69
Cramer J., Amonkar M.M., Hebborn A., and Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr. Med. Res. Opin. 21 (2005) 1453-1460
Ettinger M.P., Gallagher R., Amonkar M., Smith J.C., and MacCosbe P.E. Medication persistence is improved with less frequent dosing of bisphosphonates, but remains inadequate. Arthritis Rheum. 50 Suppl. 1 (2004) S513
Unson C.G., Siccion E., Gaztambide J., Gaztambide S., Mahoney Trella P., and Prestwood K. Non-adherence and osteoporosis treatment preferences of older women: a qualitative study. J. Women's Health 12 (2003) 1037-1045
Torgerson D.J., Iglesias C.P., and Reid D.M. The economics of fracture prevention. In: Barlow D.H., Francis R.M., and Miles A. (Eds). UK Advance Series: Key Advances in Effective Management of Osteoporosis (2000), London
Borgström F., Jönsson B., Ström O., and Kanis J.A. An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting. Based on the results of the SOTI and TROPOS trials. Osteoporos. Int. 17 (2006) 1781-1793